Crospon, the Galway-based medical device developer, has been recognised with the 2012 European Enabling Technology Award for Surgical Imaging Technology by Frost and Sullivan.
The award is in recognition of Crospon's pioneering work in the development of a leading edge minimally invasive medical device for monitoring, diagnosis, and therapy in the gastroenterology area.
The EndoFLIP (Endolumenal Functional Lumen Imaging Probe) Imaging System is a revolutionary new technology used for measuring the inner dimensions and functions of critical sphincters and lumens in the gastrointestinal tract and different parts of the body.
The EndoFLIP technology provides a direct measure of mechanical properties, such as the stretching capacity of sphincters and valves in the human body. Previously, this could not be measured directly, and doctors had to depend on indirect measures, such as manometry.
"The revolutionary EndoFLIP technology is a minimally invasive procedure designed to measure the physical properties of the esophageal or any sphincter in the body," said Frost and Sullivan Senior Research Analyst Darshana De. "It is a ten-minute procedure and allows for more accurate data compared to traditional manometry. EndoFLIP technology offers both functional and real-time imaging information of the sphincters and is a quick and low-cost option for detecting gastroesophageal reflux disease (GERD)."
Commenting on the Frost and Sullivan recognition, John O'Dea, CEO Crospon said, "Crospon is pleased to have received recognition from Frost&Sullivan for its EndoFLIP surgical imaging technology. The Company continues to build on this platform technology to move into more therapeutic focused areas including the development of smart dilation catheters with integrated imaging for esophageal disorders (EsoFLIP), and a smart valvuloplasty platform for sizing TAVI (transcatheter aortic valve implantation) valves (TAVIFLIP)."